Literature DB >> 33477672

Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy.

Marcin Skotnicki1,2, Barbara Jadach1, Agnieszka Skotnicka1, Bartłomiej Milanowski1, Lidia Tajber2, Marek Pyda3,4, Jacek Kujawski5.   

Abstract

The aim of this study was to characterize a 1:1 molar ratio of a pharmacologically relevant co-amorphous n class="Chemical">atorvastatin-irbesartan (ATR-IRB) system obtained by quench cooling of the crystalline ATR/IRB physical mixture for potential use in the fixed-dose combination therapy. The system was characterized by employing standard differential scanning calorimetry (DSC), Fourier transform-infrared spectroscopy (FT-IR), and intrinsic dissolution rate studies. Quantum mechanical calculations were performed to obtain information regarding intermolecular interactions in the studied co-amorphous ATR-IRB system. The co-amorphous formulation showed a significant improvement in the intrinsic dissolution rate (IDR) of IRB over pure crystalline as well as its amorphous counterpart. An unusual behavior was observed for ATR, as the IDR of ATR in the co-amorphous formulation was slightly lower than that of amorphous ATR alone. Short-term physical aging studies of up to 8 h proved that the ATR-IRB co-amorphous system remained in the amorphous form. Furthermore, no physical aging occurred in the co-amorphous system. FT-IR, density functional theory calculations, and analysis of T g value of co-amorphous system using the Couchman-Karasz equation revealed the presence of molecular interactions between APIs, which may contribute to the increased physical stability.

Entities:  

Keywords:  atorvastatin; co-amorphous system; density functional theory; differential scanning calorimetry; intrinsic dissolution rate; irbesartan; physical stability

Year:  2021        PMID: 33477672      PMCID: PMC7831949          DOI: 10.3390/pharmaceutics13010118

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  42 in total

Review 1.  Recent advances in co-amorphous drug formulations.

Authors:  Swapnil Jayant Dengale; Holger Grohganz; Thomas Rades; Korbinian Löbmann
Journal:  Adv Drug Deliv Rev       Date:  2016-01-21       Impact factor: 15.470

2.  Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.

Authors:  Min-Soo Kim; Shun-Ji Jin; Jeong-Soo Kim; Hee Jun Park; Ha-Seung Song; Reinhard H H Neubert; Sung-Joo Hwang
Journal:  Eur J Pharm Biopharm       Date:  2008-01-18       Impact factor: 5.571

Review 3.  Emerging trends in the stabilization of amorphous drugs.

Authors:  Riikka Laitinen; Korbinian Löbmann; Clare J Strachan; Holger Grohganz; Thomas Rades
Journal:  Int J Pharm       Date:  2012-04-28       Impact factor: 5.875

4.  Low level drug product API form analysis - Avalide tablet NIR quantitative method development and robustness challenges.

Authors:  Duohai Pan; George Crull; Shawn Yin; John Grosso
Journal:  J Pharm Biomed Anal       Date:  2013-11-20       Impact factor: 3.935

5.  Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies.

Authors:  Clifford W Fong
Journal:  Eur J Med Chem       Date:  2014-08-11       Impact factor: 6.514

6.  Revealing noncovalent interactions.

Authors:  Erin R Johnson; Shahar Keinan; Paula Mori-Sánchez; Julia Contreras-García; Aron J Cohen; Weitao Yang
Journal:  J Am Chem Soc       Date:  2010-05-12       Impact factor: 15.419

7.  Co-amorphous Formation Induced by Combination of Tranilast and Diphenhydramine Hydrochloride.

Authors:  Hiroshi Ueda; Kazunori Kadota; Masaaki Imono; Takuya Ito; Ayaka Kunita; Yuichi Tozuka
Journal:  J Pharm Sci       Date:  2016-08-15       Impact factor: 3.534

8.  Modeling of the pharmacokinetic/pharmacodynamic interaction between irbesartan and hydrochlorothiazide in normotensive subjects.

Authors:  Mohsen A Hedaya; Sally A Helmy
Journal:  Biopharm Drug Dispos       Date:  2015-02-04       Impact factor: 1.627

9.  Evaluation of drug-polymer miscibility in amorphous solid dispersion systems.

Authors:  Alfred C F Rumondor; Igor Ivanisevic; Simon Bates; David E Alonzo; Lynne S Taylor
Journal:  Pharm Res       Date:  2009-09-22       Impact factor: 4.200

10.  Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito®) in Korean adults with hypertension and hypercholesterolemia.

Authors:  Sang-Hyun Ihm; Jinho Shin; Chang-Gyu Park; Cheol-Ho Kim
Journal:  Drug Des Devel Ther       Date:  2019-02-13       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.